FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136165> ?p ?o ?g. }

• W4324136165 endingPage "103" @default.
• W4324136165 startingPage "103" @default.
• W4324136165 abstract "103 Background: Androgen deprivation therapy (ADT) has been the backbone of treatment for mHSPC for decades. In recent years, multiple randomized controlled trials demonstrating an overall survival (OS) benefit of combination treatment (e.g. ADT + novel hormonal agent and/or chemotherapy) has made this the current SOC. Large real-world reports have shown a significant number of patients are still being treated below the SOC with ADT alone, but these databases do not include patient level data to help understand the rationale for treatment decisions. We reviewed our institution’s treatment patterns for mHSPC to better understand why some patients are being treated with ADT alone. Methods: We conducted a retrospective analysis on patients who initiated treatment for mHSPC from 2017-2021 at Cleveland Clinic. Patient characteristics were recorded, including age and histology. Treatment characteristics, including location of treatment, treatment regimen, and treatment rationale (if not treated with SOC) were noted. Results: Four hundred forty-nine patients were included, with diagnosis of metastatic disease made at a median of 63 years, of which 446 started treatment with systemic therapy. The vast majority of patients were managed by a medical oncologist (95.5%). About half of the patients (49.8%) received treatment at the main campus, with the remaining patients being treated at an affiliated regional hospital (28.7%) or outpatient medical center (21.5%). Additional characteristics are shown. Out of the 446, 40 (9.0%) patients received ADT alone. Reasons for ADT monotherapy included patient preference (n = 13), cost (n = 2), and poor functional status/comorbidities (n = 4). Twenty (50%) of the patients who got ADT alone had no documented rationale for why this treatment plan was elected. One patient was lost to follow-up. For patients who received only ADT, 12 were treated at main campus, 20 were treated at a regional hospital, and 8 were treated at an outpatient medical center. Conclusions: At our institution, adherence to treatment up to SOC for mHSPC was better than previous real-world reports. There were documented reasons for not treating mHSPC up to SOC combination therapy for half of the patients who got ADT monotherapy. It remains unclear why the remaining half did not get combination therapy up to the SOC. [Table: see text]" @default.
• W4324136165 created "2023-03-15" @default.
• W4324136165 creator A5024482335 @default.
• W4324136165 creator A5031016267 @default.
• W4324136165 creator A5034605162 @default.
• W4324136165 creator A5041898186 @default.
• W4324136165 creator A5047002676 @default.
• W4324136165 creator A5065330756 @default.
• W4324136165 creator A5067380365 @default.
• W4324136165 creator A5072435293 @default.
• W4324136165 creator A5085980531 @default.
• W4324136165 date "2023-02-20" @default.
• W4324136165 modified "2023-10-06" @default.
• W4324136165 title "Adherence to standard of care (SOC) therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC): A single-institution analysis." @default.
• W4324136165 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.103" @default.
• W4324136165 hasPublicationYear "2023" @default.
• W4324136165 type Work @default.
• W4324136165 citedByCount "0" @default.
• W4324136165 crossrefType "journal-article" @default.
• W4324136165 hasAuthorship W4324136165A5024482335 @default.
• W4324136165 hasAuthorship W4324136165A5031016267 @default.
• W4324136165 hasAuthorship W4324136165A5034605162 @default.
• W4324136165 hasAuthorship W4324136165A5041898186 @default.
• W4324136165 hasAuthorship W4324136165A5047002676 @default.
• W4324136165 hasAuthorship W4324136165A5065330756 @default.
• W4324136165 hasAuthorship W4324136165A5067380365 @default.
• W4324136165 hasAuthorship W4324136165A5072435293 @default.
• W4324136165 hasAuthorship W4324136165A5085980531 @default.
• W4324136165 hasConcept C121608353 @default.
• W4324136165 hasConcept C126322002 @default.
• W4324136165 hasConcept C143998085 @default.
• W4324136165 hasConcept C2776694085 @default.
• W4324136165 hasConcept C2776907518 @default.
• W4324136165 hasConcept C2777899217 @default.
• W4324136165 hasConcept C2778311097 @default.
• W4324136165 hasConcept C2780192828 @default.
• W4324136165 hasConcept C2781413609 @default.
• W4324136165 hasConcept C71924100 @default.
• W4324136165 hasConceptScore W4324136165C121608353 @default.
• W4324136165 hasConceptScore W4324136165C126322002 @default.
• W4324136165 hasConceptScore W4324136165C143998085 @default.
• W4324136165 hasConceptScore W4324136165C2776694085 @default.
• W4324136165 hasConceptScore W4324136165C2776907518 @default.
• W4324136165 hasConceptScore W4324136165C2777899217 @default.
• W4324136165 hasConceptScore W4324136165C2778311097 @default.
• W4324136165 hasConceptScore W4324136165C2780192828 @default.
• W4324136165 hasConceptScore W4324136165C2781413609 @default.
• W4324136165 hasConceptScore W4324136165C71924100 @default.
• W4324136165 hasIssue "6_suppl" @default.
• W4324136165 hasLocation W43241361651 @default.
• W4324136165 hasOpenAccess W4324136165 @default.
• W4324136165 hasPrimaryLocation W43241361651 @default.
• W4324136165 hasRelatedWork W2098926415 @default.
• W4324136165 hasRelatedWork W2141447267 @default.
• W4324136165 hasRelatedWork W2162051638 @default.
• W4324136165 hasRelatedWork W2244450389 @default.
• W4324136165 hasRelatedWork W2299690226 @default.
• W4324136165 hasRelatedWork W2982156914 @default.
• W4324136165 hasRelatedWork W3014214351 @default.
• W4324136165 hasRelatedWork W3197369076 @default.
• W4324136165 hasRelatedWork W4297472852 @default.
• W4324136165 hasRelatedWork W2263670288 @default.
• W4324136165 hasVolume "41" @default.
• W4324136165 isParatext "false" @default.
• W4324136165 isRetracted "false" @default.
• W4324136165 workType "article" @default.